Drug
Canakinumab Injection
Canakinumab Injection is a pharmaceutical drug with 3 clinical trials. Currently 1 active trials ongoing. Historical success rate of 50.0%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
50.0%
Based on 1 completed trials
Completion Rate
50%(1/2)
Active Trials
1(33%)
Results Posted
0%(0 trials)
Terminated
1(33%)
Phase Distribution
Ph phase_4
1
33%
Ph phase_1
1
33%
Ph phase_2
1
33%
Phase Distribution
1
Early Stage
1
Mid Stage
1
Late Stage
Phase Distribution3 total trials
Phase 1Safety & dosage
1(33.3%)
Phase 2Efficacy & side effects
1(33.3%)
Phase 4Post-market surveillance
1(33.3%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
50.0%
1 of 2 finished
Non-Completion Rate
50.0%
1 ended early
Currently Active
1
trials recruiting
Total Trials
3
all time
Status Distribution
Active(1)
Completed(1)
Terminated(1)
Detailed Status
Active, not recruiting1
Completed1
Terminated1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
1
Success Rate
50.0%
Most Advanced
Phase 4
Trials by Phase
Phase 11 (33.3%)
Phase 21 (33.3%)
Phase 41 (33.3%)
Trials by Status
active_not_recruiting133%
completed133%
terminated133%
Recent Activity
1 active trials
Showing 3 of 3
active_not_recruitingphase_1
Canakinumab With Darbepoetin Alfa in PTs With Lower-Risk MDS Who Have Failed ESA
NCT04798339
completedphase_4
COVID-19 VaccinE Response in Rheumatology Patients
NCT05080218
terminatedphase_2
Efficacy and Safety of Canakinumab for the Treatment of Anemia in LR-MDS Patients
NCT05237713
Clinical Trials (3)
Showing 3 of 3 trials
NCT04798339Phase 1
Canakinumab With Darbepoetin Alfa in PTs With Lower-Risk MDS Who Have Failed ESA
NCT05080218Phase 4
COVID-19 VaccinE Response in Rheumatology Patients
NCT05237713Phase 2
Efficacy and Safety of Canakinumab for the Treatment of Anemia in LR-MDS Patients
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3